Prof.dr. P.C.M. van de Kerkhof

Pagina-navigatie:

filter results

Type

Article (263)

Date

Accessibility

Institution

Radboud University Nijmegen (263)

91-100 out of 263 results by:date

Save search results

The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis. (2007)

Authors:	Langewouters, A.M.G.; Bovenschen, H.J.; Jong, E.M.G.J. de; Erp, P.E.J. van; Kerkhof, P.C.M. van de
In:	Journal of Dermatological Treatment, 18, 279 - 285. ISSN 0954-6634.

Abstract:

BACKGROUND: Novel therapies against psoriasis are emerging. Alefacept is such a treatment. It selectively targets the memory effector population of T cells and thereby diminishes the psoriatic plaques. In some cases, however, the use of alefacept as a monotherapy is not sufficient. OBJECTIVE: In the

The evolution of the psoriatic lesion. (2007)

Author: Kerkhof, P.C.M. van de
In: British journal of dermatology, 157, 4 - 15. ISSN 0007-0963.

Abstract:
Psoriasis comprises a host of abnormalities, and various aspects of the pathogenesis of psoriasis have been suggested to be of primary relevance. The aim of this review is to identity driving factors in the pathogenesis of psoriasis and to explore the dynamics of processes eventually resulting in a

Author:	Kerkhof, P.C.M. van de
In:	British journal of dermatology, 157, 4 - 15. ISSN 0007-0963.

Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. (2007)

Authors:	Bovenschen, H.J.; Gerritsen, W.J.; Rens, D.W.A. van; Seyger, M.M.B.; Jong, E.M.G.J. de; Kerkhof, P.C.M. van de
In:	Archives of Dermatological Research, 298, 457 - 463. ISSN 0340-3696.

Abstract:

The aim of this study was to explore the additional effect of betamethasone dipropionate cream in the early phase of an intramuscular (IM) alefacept course, on plaque severity and on modulating T-cell subsets, cells expressing NK-receptors, epidermal proliferation and keratinocyte differentiation in

Invloed van huidaandoeningen op het dagelijks leven (IHDL) : Een ziektespecifiek en generiek meetinstrument voor chronische huidaandoeningen (2007)

Authors:	Evers, A.W.M.; Duller, P.; Kerkhof, P.C.M. van de; Valk, P.G.M. van der; Gerritsen, M.J.P.; Kooijmans-Otero, M.E.; Verhoeven, E.W.M.; Kraaimaat, F.W.
In:	Psychologie en Gezondheid, 35, 40 - 49. ISSN 1873-1791.

A 'muscle' man without exercise: muscle pseudohypertrophy in myeloma-associated generalized amyloidosis. (2007)

Authors:	Sibelt, L.A.G.; Lokhorst, H.M.; Kerkhof, P.C.M. van de; Dooren-Greebe, R.J. van
In:	Journal of the European Academy of Dermatology and Venereology, 21, 986 - 988. ISSN 0926-9959.

Oral retinoic acid metabolism blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. (2007)

Authors:	Bovenschen, H.J.; Kooijmans-Otero, M.E.; Langewouters, A.M.G.; Vlijmen-Willems, I.M.J.J. van; Rens, D.W.A. van; Seyger, M.M.B.; Kerkhof, P.C.M. van de
In:	British journal of dermatology, 156, 263 - 270. ISSN 0007-0963.

Abstract:

BACKGROUND: The novel systemic all-trans retinoic acid metabolism blocking agent (RAMBA) R115866 (Rambazole(TM); Barrier Therapeutics, Geel, Belgium; further referred to as rambazole) increases intracellular levels of endogenous all-trans retinoic acid (RA). Well-known effects of RA are normalizatio

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. (2007)

Authors:	Berends, M.A.M.; Driessen, R.J.B.; Langewouters, A.M.G.; Boezeman, J.B.M.; Kerkhof, P.C.M. van de; Jong, E.M.G.J. de
In:	Journal of Dermatological Treatment, 18, 76 - 83. ISSN 0954-6634.

Abstract:

BACKGROUND: Since the beginning of 2005, etanercept and efalizumab are officially registered and reimbursed for the treatment of recalcitrant psoriasis in The Netherlands. OBJECTIVE: The evaluation of the efficacy, safety and adverse events of etanercept and efalizumab treatment in daily practice. M

Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity? (2007)

Authors: Kerkhof, P.C.M. van de; Mrowietz, U.; Segaert, S.; Kragballe, K.
In: British journal of dermatology, 156, 771 - 772. ISSN 0007-0963.
Ulcer-related problems and health care needs in patients with venous leg ulceration: a descriptive, cross-sectional study. (2007)

Authors: Heinen, M.M.; Persoon, A.; Kerkhof, P.C.M. van de; Otero, M.; Achterberg, T. van
In: International Journal of Nursing Studies, 44, 1296 - 1303. ISSN 0020-7489.

Abstract:
BACKGROUND: Patients with leg ulceration often have long lasting and recurrent wounds. The treatment exists mainly of wound-care and compression therapy. International literature shows several indications of problems in relation to leg ulceration, but no studies were performed to give a comprehensiv

Authors:	Kerkhof, P.C.M. van de; Mrowietz, U.; Segaert, S.; Kragballe, K.
In:	British journal of dermatology, 156, 771 - 772. ISSN 0007-0963.

Authors:	Heinen, M.M.; Persoon, A.; Kerkhof, P.C.M. van de; Otero, M.; Achterberg, T. van
In:	International Journal of Nursing Studies, 44, 1296 - 1303. ISSN 0020-7489.

Sedentary patients with venous or mixed leg ulcers: determinants of physical activity. (2007)

Authors:	Heinen, M.M.; Evers, A.W.M.; Uden, C. van; Vleuten, C.J.M. van der; Kerkhof, P.C.M. van de; Achterberg, T. van
In:	Journal of Advanced Nursing, 60, 50 - 57. ISSN 0309-2402.

Abstract:

AIM: This paper is a report of a study to identify the determinants of physical activity (PA) in patients with venous leg ulcers to develop recommendations for behavioural interventions aimed at enhancing physical activity. BACKGROUND: Physical activity promotes wound healing and prevents the recurr

Pages:

<< < 6 7 8 9 10 11 12 13 14 15 > >>